The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Multitarget Therapy for Induction Treatment of Lupus Nephritis: A Randomized Trial
Abstract
BACKGROUND: Treatment of lupus nephritis (LN) remains challenging. OBJECTIVE: To assess the efficacy and safety of a multitarget therapy consisting of tacrolimus, mycophenolate mofetil, and steroid compared with intravenous cyclophosphamide and steroid as induction therapy for LN. DESIGN: 24-week randomized, open-label, multicenter study. (ClinicalTrials.gov: NCT00876616). SETTING: 26 renal centers in China. PATIENTS: Adults (aged 18 to 65 years) with biopsy-proven LN. INTERVENTION: Tacrolimus, 4 mg/d, and mycophenolate mofetil, 1.0 g/d, versus intravenous cyclophosphamide with a starting dose of 0.75 (adjusted to 0.5 to 1.0) g/m2 of body surface area every 4 weeks for 6 months. Both groups received 3 days of pulse methylprednisolone followed by a tapering course of oral prednisone therapy. MEASUREMENTS: The primary end point was complete remission at 24 weeks. Secondary end points included overall response (complete and partial remission), time to overall response, and adverse events. RESULTS: After 24 weeks of therapy, more patients in the multitarget group (45.9%) than in the intravenous cyclophosphamide group (25.6%) showed complete remission (difference, 20.3 percentage points [95% CI, 10.0 to 30.6 percentage points]; P < 0.001). The overall response incidence was higher in the multitarget group than in the intravenous cyclophosphamide group (83.5% vs. 63.0%; difference, 20.4 percentage points [CI, 10.3 to 30.6 percentage points]; P < 0.001), and the median time to overall response was shorter in the multitarget group (difference, -4.1 weeks [CI, -7.9 to -2.1 weeks]). Incidence of adverse events did not differ between the multitarget and intravenous cyclophosphamide groups (50.3% [91 of 181] vs. 52.5% [95 of 181]). LIMITATION: The study was limited to 24 weeks of follow-up. CONCLUSION: Multitarget therapy provides superior efficacy compared with intravenous cyclophosphamide as induction therapy for LN. PRIMARY FUNDING SOURCE: National Basic Research Program of China, National Key Technology R&D Program.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mathematical Statistics and Data Analysis
Rabinowitz, L. (1989) · Technometrics · doi:10.1080/00401706.1989.10488573 · Cited by 3,116
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited
Weening, J. J., D’Agati, V. D., Schwartz, M. M., Seshan, S. V., Alpers, C. E., Appel, G. B., Balow, J. E., Bruijn, J. A., Cook, T., Ferrario, F., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000108969.21691.5d · Cited by 2,008
The prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067411 · Cited by 1,810
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
Ginzler, E. M., Dooley, M. A., Aranow, C., Kim, M. Y., Buyon, J., Merrill, J. T., Petri, M., Gilkeson, G. S., Wallace, D. J., Weisman, M. H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043731 · Cited by 1,128
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., Li, L.-S., Mysler, E., Sa[Combining Acute Accent]nchez-Guerrero, J., Solomons, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008101028 · Cited by 1,118
Faul, C., Donnelly, M., Merscher-Gomez, S., Chang, Y. H., Franz, S., Delfgaauw, J., Chang, J.-M., Choi, H. Y., Campbell, K. N., Kim, K., et al. (2008) · Nature Medicine · doi:10.1038/nm.1857 · Cited by 991
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
Chan, T. M., Li, F. K., Tang, C. S. O., Wong, R. W. S., Fang, G. X., Ji, Y. L., Lau, C. S., Wong, A. K. M., Tong, M. K. L., Chan, K. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431604 · Cited by 954
Application of random-effects pattern-mixture models for missing data in longitudinal studies.
Hedeker, D., & Gibbons, R. D. (1997) · Psychological Methods · doi:10.1037/1082-989x.2.1.64 · Cited by 907
Prognostic factors in lupus nephritis
Austin, H. A., Muenz, L. R., Joyce, K. M., Antonovych, T. T., Kullick, M. E., Klippel, J. H., Decker, J. L., & Balow, J. E. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90338-8 · Cited by 803
Austin, H. A., Muenz, L. R., Joyce, K. M., Antonovych, T. T., & Balow, J. E. (1984) · Kidney International · doi:10.1038/ki.1984.75 · Cited by 718
Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis
Dooley, M. A., Jayne, D., Ginzler, E. M., Isenberg, D., Olsen, N. J., Wofsy, D., Eitner, F., Appel, G. B., Contreras, G., Lisk, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014460 · Cited by 642
Frailty models for survival data
Hougaard, P. (1995) · Lifetime Data Analysis · doi:10.1007/bf00985760 · Cited by 582
Adjustments for Center in Multicenter Studies: An Overview
Localio, A. R., Berlin, J. A., Ten Have, T. R., & Kimmel, S. E. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00012 · Cited by 442
Predicting renal outcomes in severe lupus nephritis: Contributions of clinical and histologic data
Austin, H. A., Boumpas, D. T., Vaughan, E. M., & Balow, J. E. (1994) · Kidney International · doi:10.1038/ki.1994.70 · Cited by 407
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study
Isenberg, D., Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Jayne, D., Sánchez-Guerrero, J., Wofsy, D., Yu, X., & Solomons, N. (2010) · Rheumatology · doi:10.1093/rheumatology/kep346 · Cited by 356
Value of a Complete or Partial Remission in Severe Lupus Nephritis
Chen, Y. E., Korbet, S. M., Katz, R. S., Schwartz, M. M., & Lewis, E. J. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03280807 · Cited by 312
Successful Treatment of Class V+IV Lupus Nephritis with Multitarget Therapy
Bao, H., Liu, Z.-H., Xie, H.-L., Hu, W.-X., Zhang, H.-T., & Li, L.-S. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007121272 · Cited by 301
Self-citationONG, L. M., HOOI, L. S., LIM, T. O., GOH, B. L., AHMAD, G., GHAZALLI, R., TEO, S. M., WONG, H. S., TAN, S. Y., SHAARIAH, W., et al. (2005) · Nephrology · doi:10.1111/j.1440-1797.2005.00444.x · Cited by 252
Chen, W., Tang, X., Liu, Q., Chen, W., Fu, P., Liu, F., Liao, Y., Yang, Z., Zhang, J., Chen, J., et al. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.08.036 · Cited by 202
Self-citationUpdates on the Treatment of Lupus Nephritis
Bomback, A. S., & Appel, G. B. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010050472 · Cited by 177
The long-term outcome of 93 patients with proliferative lupus nephritis
Moroni, G., Quaglini, S., Gallelli, B., Banfi, G., Messa, P., & Ponticelli, C. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm245 · Cited by 173
Therapeutic monitoring of mycophenolic acid
Shaw, L. M. J., Nicholls, A. J., Hale, M., Armstrong, V. W., Oellerich, M., Yatscoff, R., Morris, R. E., Holt, D. W., Venkataramanan, R., Haley, J., et al. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00040-x · Cited by 127
A comparison of frailty models for multivariate survival data
Pickles, A. R., & Crouchley, R. (1995) · Statistics in Medicine · doi:10.1002/sim.4780141305 · Cited by 126
Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis
Szeto, C., Kwan, B. C., Lai, F. M., Tam, L., Li, E. K.-M., Chow, K.-M., Gang, W., & Li, P. K.-T. (2008) · Rheumatology · doi:10.1093/rheumatology/ken335 · Cited by 123
Ekberg, H., Bernasconi, C., Noeldeke, J., Yussim, A., Mjörnstedt, L., Erken, U., Ketteler, M., & Navrátil, P. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp778 · Cited by 123
Wang, H., Cui, T., Hou, F., Ni, Z., Chen, X., Lu, F., Xu, F., Yu, X., Zhang, F. S., Zhao, X., et al. (2008) · Lupus · doi:10.1177/0961203308089408 · Cited by 103
Self-citationYap, D. Y. H., Yu, X., CHEN, X., Lu, F., Chen, N., Li, X., TANG, C. S., & Chan, T. M. (2012) · Nephrology · doi:10.1111/j.1440-1797.2012.01574.x · Cited by 82
Self-citationCalcineurin (CN) Activation Promotes Apoptosis of Glomerular Podocytes Both in Vitro and in Vivo
Wang, L., Chang, J., Paik, S.-Y., Tang, Y., Eisner, W., & Spurney, R. F. (2011) · Molecular Endocrinology · doi:10.1210/me.2011-0029 · Cited by 74
Mycophenolate mofetil in the treatment of systemic lupus erythematosus
Dall’Era, M. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328349a1e5 · Cited by 57
Lee, Y. H., Lee, H.-S., Choi, S., Ji, J. D., & Song, G. G. (2011) · Lupus · doi:10.1177/0961203310389486 · Cited by 54
Tacrolimus is effective for lupus nephritis patients with persistent proteinuria.
Uchino, A., Tsukamoto, H., Nakashima, H., Yoshizawa, S., Furugo, I., Mitoma, H., Oryoji, K., Shimoda, T., Niiro, H., Tada, Y., et al. (2010) · PubMed · Cited by 40
Lupus nephritis. How latest insights into its pathogenesis promote novel therapies
Kulkarni, O. P., & Anders, H. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328354c877 · Cited by 23
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citation2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215089 · Cited by 2,011
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Fanouriakis, A., Kostopoulou, M., Andersen, J., Aringer, M., Arnaud, L., Bae, S.-C., Boletis, J., Bruce, I. N., Cervera, R., Doria, A., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-224762 · Cited by 1,081
Anders, H.-J., Saxena, R., Zhao, M.-H., Parodis, I., Salmon, J. E., & Mohan, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0141-9 · Cited by 958
Almaani, S., Meara, A., & Rovin, B. H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05780616 · Cited by 930
Metadata
- Authors
- Liu, Z., Zhang, H., Liu, Z., Xing, C., Fu, P., Ni, Z., Chen, J., Lin, H., Liu, F., He, Y., He, Y., Miao, L., Chen, N., Li, Y., Gu, Y., Shi, W., Hu, W., Liu, Z., Bao, H., Zeng, C., & Zhou, M.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2015-01-06
- Volume
- 162
- Issue
- 1
- Pages
- 18-26
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2073246129
- Cited by
- 396
- References
- 33
- FWCI
- 21.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.